soft caus concern
edward report rev consensu estim
sale adjust surgic heart valv consign convers also miss
benefit lower tax rate essenti in-lin guidanc maintain
tone call unmistak cautiou highlight concern
underneath tweak forward estim
concern
compani stop give tavr split ou
partli obfusc true growth number unless math wrong edward
market share europ declin bp last qtr
declin market share concern given price
 premium corevalv qtr lower market
procedur growth rate edward unclear us introduct
ultra centerra price premium result step-chang
cannib mayb seem price elast demand increas
europ henc caution warrant true impact ultra
world-wide tavr number soft util procedures/day
sequenti ou util flattish last qtr
commentari edward edge-edg mitral repair product pascal indic
europ launch pascal expect sometim late howev detail
data present ce mark trial look like provid
compani receiv fda approv start pivot studi pascal
primari mr random patient non-inferior studi
mitraclip suspect oct note edward greater
risk chang compar arm pascal trial coapt
indic edward updat note field check europ
edward tmvr program weak whether cardiaq sapien
matter cardioband even pascal feedback rel
mix view coapt chang mitral landscap whether
believ generaliz coapt result edward somewhat
box play catch-up absent demonstr better data
mitraclip see one get enthusiast edward stock
level let alon soft tavr number quarter row
lower forward estim despit structur benefit realiz
lower tax rate rate continu reflect tavr growth
rate slow tmvr program edward sort drift along
stock pt without real catalyst horizon
ew report number leav much desir world-wide sale miss
consensu estim respect adjust sale adjust surgic heart
valv consign convers net relat cost respect relat convers
consign inventori system surgic heart valv world-wide tavr revenu also miss
consensu estim respect compani stop provid tavr split
 ou number although state growth impli us tavi rev came gaap
tavi sale non-gaap tavi sale royalti sale return reserv vs estim
underli tavi sale y/i as-report basi impli ou tavi rev seem
rang y/i compani indic fx bp neg impact qtr off-set
favor product mix shift result gross margin world-wide tavr sale y/i
although sequenti asp stabl across region edwardss procedur growth
roughli line market growth ou compani indic procedur growth
y/i lower market growth compani lost share especi due competitor lower price
remind asp almost higher medtron tavr growth japan also
strong although specif japan franc provid compani indic japan growth
continu driven high-risk patient europ overal market growth rang
centerra self-expand system launch on-going slight price premium recent field
check indic europ share roughli rang edward other
respect commentari aggreg continu blurri extent intermediate-risk market penetr
extent contribut guidanc
thing mention note
compani indic competitor still compet price although edward maintain
price point rational given sapien except outcom make strateg sens
engag price war
launch ultra centerra bring premium featur rich platform lead edward
believ price disadvantag next year
centerra expect price premium although specif provid
unclear contribut ou tavr growth come de novo implant vs price premium
centerra current price elast demand clear also unclear valu proposit
centerrawil improv procedur time enough justifi increas asp improv
outcom drastic justifi increas asp count seriou doubt
market support even higher price point
growth mid-teen ou procedur growth edward lower market growth
remind care need exercis extrapol procedur growth sale growth
ou edward given price premium dont specif
page
rough math indic price stabl edward net procedur growth lower market
continu hemorrhag market share price elast demand increas
new center place qtr highlight although total center littl
math suggest world-wide edward roughli center
compani clarifi exact contribut intermediate-risk especi math
indic utilization/day revert back normal although ou us
util rate shown wherea ou rang ou procedur
volum bare budg last quarter interestingli procedures/day tick sequenti
 flattish ou despit season preval ou
figur approx tavr procedures/day geographi
japan tavr contribut quarter specif state although compani state japan
one strongest growth area ou wonder ou growth exclud japan especi
europ would
edward indic us tavr growth come littl center although
number new center state dont number would fascin
deep-div sales-rep product stratifi volum procedur per center
commentari call indict europ tavi procedur growth rang
edward growth europ word market growth straight quarter
confess reconcil edward commentari procedur growth vs price vs
market share europ ou guesstim roughli center activ involv tavi
procedur rememb as-report y/i growth europ specif state
guesstim approx sapien sold approx hospit ou impli rate approx
sequenti sale rate assum center seem around
sequenti basi
interest note pure surgic aortic valv basi util rate base
field check usual around henc metric tavi penetr
util come rather quickli bear mind util rate would also need
ad edward number would need compar aggreg util rate
page
savr state otherwis cannib intermedi risk patient tavi occur full swing post-
sapien launch expect growth rate skyrocket even
surgic heart valv exclud vascular surgeri repair base report number
y/i note past quarterli run rate surgic heart valv approx
run rate world-wide math indic segment approx flattish sequenti
essenc surgic heart valv continu downward past year despit higher
like valv magna eas mitral aortic intuiti elit
contribut tavr sale uk state remind guidelin recent call
expand use tavr
final could anoth cloud horizonth medcac meet held baltimor earlier
week specif tri answer question level procedur volum hospit
necessari tavr certif unclear final ncd shape bodi languag seem
indic could risk current structur landscap whether reimburs hospit
restrict competit shift final ncd due earli novemb although edward remain
confid wont materi chang polici would hinder broad adopt
sale cardioband recogn qtr origin guidanc cardioband
contribut reiter compani indic manufactur constraint blame
poor sale compani transit manufactur acquir israel facil
edward facil howev confess someth add miss cardioband
contribut signific manufactur issu entir explain delta sure edward
must task integr team perform due dilig manufactur cardioband
valtech israel facil less year later start shift product headscratch
ehav alway state rational valtech deal never made sens us past edward
indic look simplifi patient protocol make product enhanc cardioband
make adapt tricuspid use also call compani highlight creation
separ cardioband mitral sale team ground hire requisit folk take longer
expect lead slower ramp rate origin assess cardioband remainswhil edward
probabl look gather ip mitral repair space cardioband procedur technic
demand field check europ point encourag outcom matter
product adapt widespread use
interestingli virtual mention cardiaq tmvr program statu ce studi
transap approach compani lay groundwork move sapien
platform via transsept rout check europ continu indic cardiaq program
essenti troubl understand key member origin cardiaq team
left edward importantli recent field check also encourag
hesit say edward outmaneuv abbott tmvr space
fact remain still complic two-step procedur compar intrepid tendyn
alreadi start intrepid system abbott announc yesterday studi
tendyn valv one worri edward first mover advantag still mire
figur deliveri mechan
edward transcath mitral repair product pascal expect gain ce mark although specif
time detail data trial design provid edward receiv irb
approv start pivot trial pascal degen mr addit detail provid trial
includ random patient non-inferior studi dmr compar abbott mitraclip
state note date octob real possibl pascal program would need
reconfigur includ mitraclip compar arm edward announc
primari mr essenti valid concern question mind trial besid primari
endpoint mr grade reduct secondari endpoint qol criteria multipl clip per patient
allow time per procedur mr-grade follow discharg select bia figur
final outcom
enrol low-risk trial complet data present expect cap on-going
although minim contribut low-risk indic approv expect later although compani
seem alreadi temper expect ramp low-risk post approv
earli tavr trial enrol start rememb earli tavr asymptomat sever patient
page
updat harpoon call compani state ce mark harpoon
chordal repair devic wit earli event patient lead compani
re-evaluate product design trial design compani indic slowli start treat patient
figur order tavi sale geographi mm segment rev mm
guidanc updat follow
world-wide tavi sale higher end guidanc critic higher end
segment guidanc surgic heart valv guidanc higher end guidanc
overal revenu guidanc
gross margin expect rang adjust ep essenti unchang
primari driver y/i ep growth seem tax benefit
 sale sg sale
page
tax rate lower end sale due impact new acctg impact stock option expens new
tax law ou earn repatri
estim lower sale ep goe
figur approx util metric world-wide basi
like edward long-term fundament stori howev struggl find catalyst would drive step
perform current expect stock pt dont confid edward
transcathet mitral endeavor least base current evid remain still use rational
approx tavi sale non-tavi biz tmvr piec till viabil mitral program
establish hard time justifi signific increas pt
page
statement oper
number mm round
good sold
sg
page
edward lifesci world leader surgic heart valv sapien platform transcathet heart valv
also current posit world
pt deriv use sum part methodolog
risk achiev price target
suraj kalia certifi view express report accur reflect person view
subject compani secur part compens directli
indirectli relat specif recommend view express report
